Plasma proteomic signature predicts who will get persistent symptoms following SARS-CoV-2 infection

Gabriella Captur(Royal Free London NHS Foundation Trust), Wendy Heywood(Great Ormond Street Hospital), Daniel M. Altmann(Imperial College London), Rosemary J. Boyton(Hammersmith Hospital), Mahdad Noursadeghi(Institute of Infection and Immunity), Constantin‐Cristian Topriceanu(University College London), Tim Brooks, Thomas A. Treibel(National Institutes of Health), Nina Patel(Great Ormond Street Hospital), Kevin Mills(Great Ormond Street Hospital), Áine McKnight(Queen Mary University of London), Charlotte Manisty(National Institutes of Health), Marianna Fontana(Amyloidosis Foundation), George Joy(St Bartholomew's Hospital), Ivan Doykov(Great Ormond Street Hospital), Leo Swadling(University of Oxford), Benjamin O’Brien(St Bartholomew's Hospital), Tomas Baldwin(Great Ormond Street Hospital), Katia Menacho(St Bartholomew's Hospital), Jenny Hällqvist(Queen Mary University of London), Mala K. Maini(California Institute of Technology), Justyna Śpiewak(Great Ormond Street Hospital), Corrina Pade(Queen Mary University of London), James Moon(University of Michigan), Matt Hamblin(St Bartholomew's Hospital), Joseph M. Gibbons(Queen Mary University of London)
EBioMedicine
September 28, 2022
Cited by 70


Related Papers